Dupixent Faces Second Re-Pricing in August with 11.7% Cut

Sanofi’s atopic dermatitis and asthma drug Dupixent (dupilumab) will be hit by its second market expansion re-pricing in Japan with a price slash of 11.7% to be implemented in August. The re-pricing plan was reported to a reimbursement policy panel...read more